논문KCI 등재
GULP1, a multifaceted diagnostic biomarker and po tential therapeutic target in hepatocellular carcinoma: Editorial on “GULP1 as a novel diagnostic and predic tive biomarker in hepatocellular carcinoma”
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Unveiling GULP1 as a hepatocyte-specific role for re currence: Editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Ning Wang, Pengde Lu대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호GULP1: New hope for hepatocellular carcinoma: Reply to correspondence on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”John Wurpel, Lu-Qi Cao, Yuhao Xie, Zhe-Sheng Chen대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Sheng Zheng, Xinyi Li대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial on “GULP1 as a novel di agnostic and predictive biomarker in hepatocellular carcinoma”Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepato cellular carcinoma”Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호A novel link between tumor cell metabolism and pa tient prognosis: Editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”Eun Ji Jang, Pil Soo Sung대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12